Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. Find the latest AstraZeneca PLC (AZN) stock quote, history, news and other vital information to help you with your stock trading and investing.

    • Historical Data

      Explore the historical performance of AstraZeneca PLC (AZN)...

    • Analysis

      See AstraZeneca PLC (AZN) stock analyst estimates, including...

    • Stock Forum & Discussion

      Find the latest AstraZeneca PLC (AZN) stock discussion in...

    • Statistics

      Find out all the key statistics for AstraZeneca PLC (AZN),...

    • Holders

      Find out the direct holders, institutional holders and...

    • Profile

      See the company profile for AstraZeneca PLC (AZN) including...

    • Financials

      Get the detailed quarterly/annual income statement for...

    • Sustainability

      See AstraZeneca PLC (AZN) Environment, Social and Governance...

  2. Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know. In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous...

  3. 1 ημέρα πριν · Should You Buy or Sell AstraZeneca Stock? Get The Latest AZN Stock Analysis, Price Target, Dividend Info, Headlines, and Short Interest at MarketBeat.

  4. 20 Νοε 2021 · Getting will-call delivery from UPS is not so hard. In fact, in times of COVID, many are choosing it as their preferred option to get their packages. Luckily, the process is not difficult, especially if you already know what you are doing. You can use your UPS InfoNotice to arrange for will-call.

  5. 17 Οκτ 2023 · Want to buy AstraZeneca stock? This complete guide will take you through every step of the process. Ideal for beginner traders.

  6. You can have your shipment picked up from your home or office by scheduling your pickup online at the link below or by calling 1-800-PICK-UPS ® (1-800-742-5877). UPS will pick up all packages with a single pickup request; you’ll not be charged additional pickup fees per package.

  7. 5 Μαΐ 2022 · DELIVER was an international, randomised, double-blind, parallel-group, placebo-controlled, event-driven Phase III trial designed to evaluate the efficacy of Farxiga, compared with placebo, in the treatment of HF patients with LVEF greater than 40% with or without T2D.